William Blair Reaffirms Market Perform Rating for Eyenovia (NASDAQ:EYEN)

Eyenovia (NASDAQ:EYEN)‘s stock had its “market perform” rating restated by William Blair in a research note issued on Friday,Benzinga reports. William Blair also issued estimates for Eyenovia’s Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.47) EPS, Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.37) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Eyenovia in a research report on Wednesday.

Eyenovia Stock Down 70.0 %

Shares of EYEN opened at $0.10 on Friday. The company has a current ratio of 0.74, a quick ratio of 0.27 and a debt-to-equity ratio of 0.58. Eyenovia has a 12 month low of $0.09 and a 12 month high of $2.57. The firm’s 50 day moving average is $0.49 and its 200-day moving average is $0.71. The stock has a market capitalization of $6.53 million, a PE ratio of -0.14 and a beta of 1.75.

Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same quarter last year, the firm posted ($0.18) EPS. Equities research analysts forecast that Eyenovia will post -0.56 EPS for the current year.

Insider Buying and Selling at Eyenovia

In other Eyenovia news, CEO Michael M. Rowe purchased 50,000 shares of the stock in a transaction dated Monday, August 26th. The stock was bought at an average price of $0.57 per share, with a total value of $28,500.00. Following the acquisition, the chief executive officer now owns 82,927 shares of the company’s stock, valued at approximately $47,268.39. This represents a 151.85 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 7.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eyenovia in the 2nd quarter valued at approximately $26,000. Ground Swell Capital LLC bought a new position in Eyenovia in the 2nd quarter valued at approximately $27,000. Nations Financial Group Inc. IA ADV boosted its position in Eyenovia by 24.4% in the second quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock valued at $30,000 after buying an additional 10,000 shares in the last quarter. Financial Management Network Inc. bought a new stake in shares of Eyenovia during the third quarter worth $39,000. Finally, SkyView Investment Advisors LLC acquired a new position in shares of Eyenovia during the second quarter worth $87,000. Institutional investors own 25.84% of the company’s stock.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.